Trial
NCT02277093
Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Washington University School of Medicine
Collaborators
CTI BioPharma
Condition
Colorectal Cancer
Intervention
Pacritinib
Why stopped
FDA issued a clinical hold as pacritinib had increased side effects
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-05-01